What is Quibim?
Quibim operates at the intersection of artificial intelligence and radiology, providing a comprehensive whole-body imaging ecosystem known as Quibim Precision. The company specializes in the extraction of quantitative imaging biomarkers, which allow for the precise detection of pathologies and the monitoring of treatment efficacy across diverse imaging modalities. By adopting an AI-first methodology, Quibim addresses the growing demand for data-driven insights in clinical workflows, effectively bridging the gap between raw imaging data and actionable medical intelligence. Its market position is defined by its ability to support complex research applications while maintaining the scalability required for enterprise-level healthcare deployments.
How much funding has Quibim raised?
Quibim has raised a total of $50M across 1 funding round:
Series A
$50M
Series A (2025): $50M with participation from Asabys Partners, GoHub Ventures, and UI Investissement
Key Investors in Quibim
Asabys Partners
Asabys Partners is an investment firm based in Barcelona that focuses on fostering breakthrough innovation in healthcare and life sciences, aiming to improve patient outcomes through disruptive advancements.
GoHub Ventures
GoHub Ventures is an early-stage venture capital fund that invests in founders developing B2B software and digital health solutions, with a specific focus on artificial intelligence and operational efficiency.
UI Investissement
UI Investissement supports the growth of small and medium businesses across France, providing strategic capital and operational expertise to help companies reach their full potential.
What's next for Quibim?
With this major enterprise-level funding, Quibim is strategically positioned to deepen its research and development efforts, particularly in the refinement of its AI algorithms for broader diagnostic applications. The company is expected to focus on enhancing its imaging biomarkers to cover a wider array of pathologies, thereby increasing the utility of its platform for pharmaceutical partners and clinical institutions. Furthermore, the capital will likely support the expansion of its commercial infrastructure, enabling the firm to penetrate new geographic markets and solidify its status as a global leader in medical imaging analysis. As the healthcare industry continues to prioritize digital transformation, Quibim's focus on quantitative precision will be instrumental in driving the next generation of patient-centric diagnostic solutions.
See full Quibim company page
